Home >> Marketplace Directory >> New clearance for MammaPrint FFPE test, 4/15

New clearance for MammaPrint FFPE test, 4/15

image_pdfCreate PDF

April 2015—Agendia received 510(k) clearance from the Food and Drug Administration for its MammaPrint breast cancer recurrence test in formalin-fixed, paraffin-embedded tissue. The MammaPrint FFPE test uses the same 70 genes and proprietary algorithm as the previously cleared MammaPrint Fresh.

Agendia , 888-321-2732

CAP TODAY
X